Personalized Stem Cells Co-Founder and Chief Scientific Officer, Dr. Bob Harman, will be speaking at an upcoming event that focuses on Cellular Therapies and Transfusion Medicine in Trauma and Critical Care. The CTTACC conference will take place on December 11-13, 2019 in San Diego, California.
PSC Co-Founder and Chief Scientific Officer, Dr. Bob Harman
Dr. Harman has been asked to participate as a panelist in a session entitled Optimizing Cell Product Development and Delivery to Patients, which will take place on Wednesday, December 11th at 5pm. According to Dr. Harman, Trauma creates a major need for stem cells. Since stem cells have been shown to act immediately to reduce cell death, modulate inflammation, block pain, and reduce fibrosis, it is clear there is place for cell therapy in trauma and critical care medicine.
PSC’s sister company, VetStem Biopharma, is in final phase 3 FDA approved clinical studies and has developed an entire “commercial” system to produce and deliver off-the-shelf stem cells to veterinary clinics. This system will be shared with the audience in the panel discussion to demonstrate translational medicine from veterinary to human clinical use. The technology encompasses all aspects from donor selection, cGMP cell production, and the logistics and format of delivery of the product to the clinician ready to inject.